Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

Disc Medicine reported positive initial Phase 2 RESTORE-PV data for DISC-3405 in polycythemia vera, showing increased hepcidin and lower serum iron that reduced phlebotomy needs, controlled hematocrit, and improved symptom burden. The company will present the data orally at the SOHO meeting on September 10 and also reiterated positive Phase 2 RALLY-MF results for selcodebart in myelofibrosis-associated anemia.

Analysis

The investable question is whether DISC-3405 can demonstrate a clinically meaningful and durable reduction in phlebotomy burden without creating iron-restriction toxicity that limits chronic dosing. A hepcidin-based mechanism could differentiate from cytoreductive therapies by addressing erythrocytosis while potentially avoiding some tolerability barriers, but Phase 2 signals will not justify a commercial valuation reset absent patient-level durability, dose-response, discontinuation, and thrombotic-event data. The September 10 oral presentation is therefore a near-term volatility catalyst rather than confirmation of de-risking.

Competitive implications are most relevant for Protagonist Therapeutics (PTGX), whose rusfertide program targets the same PV treatment gap. Strong durability and safety from IRON would validate the hepcidin pathway but could reduce PTGX's eventual scarcity premium if DISC-3405 appears differentiated on dosing convenience, symptom benefit, or iron-management profile; conversely, weak durability would concentrate value in PTGX. Incyte (INCY) has less direct revenue risk near term because its PV franchise serves a more established treatment line, though a successful non-cytoreductive option could pressure long-run switching economics.

Consensus may over-credit mechanistic biomarker movement before seeing hard clinical endpoints. The key valuation sensitivity over the next 1-3 months is not simply hematocrit control, but whether results compare favorably with historical phlebotomy-free control rates and whether safety supports broad use in a chronic, relatively stable population. Six-to-eighteen-month upside requires a registrationally credible development path and adequate cash runway; neither can be inferred from a conference poster.

Key Decisions for Investors

• Do not chase IRON solely on the poster release; place a catalyst watch for the September 10 presentation and initiate only if the dataset shows durable phlebotomy reduction, clean discontinuation rates, and no material thrombosis or iron-deficiency signal. A failure on any of those endpoints would invalidate a near-term long thesis.
• If oral-presentation details establish differentiation versus historical PV benchmarks, consider a 1-3 month tactical long IRON sized small, with a 15-20% downside stop and target of 30-40% upside into fuller dataset/regulatory-path disclosure; this is a binary clinical-data trade, not a core holding.
• Monitor PTGX as the cleaner liquid competitive readthrough: stronger-than-expected IRON data may create a short-term opportunity to reduce PTGX exposure on pathway-validation enthusiasm, while evidence of tolerability or durability limitations at IRON would favor long PTGX versus IRON.
• Require updated IRON cash balance, quarterly burn, planned pivotal-trial design, and manufacturing/dosing details before underwriting a 6-18 month position. A financing need before a registrational catalyst would likely cap multiple expansion even if the biology remains intact.